Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply.
Saved in:
| Title: | Letter: should HCV cirrhotics with high bilirubin or Gilbert's syndrome be excluded from paritaprevir, ombitasvir, or dasabuvir? Authors' reply. |
|---|---|
| Authors: | Banerjee D; Division of Gastroenterology/Hepatology, University of Pennsylvania, Philadelphia, PA, USA., Reddy KR; Division of Gastroenterology/Hepatology, University of Pennsylvania, Philadelphia, PA, USA. rajender.reddy@uphs.upenn.edu. |
| Source: | Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2016 May; Vol. 43 (9), pp. 1022-3. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8707234 Publication Model: Print Cited Medium: Internet ISSN: 1365-2036 (Electronic) Linking ISSN: 02692813 NLM ISO Abbreviation: Aliment Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1365-2036 |
|---|---|
| DOI: | 10.1111/apt.13586 |
